Schulz et al. Acta Neuropathologica Communications 2014, 2:82
http://www.actaneurocomms.org/content/2/1/82

R EV I E W
A neuronal function of the tumor suppressor
protein merlin
Alexander Schulz1,2, Ansgar Zoch1 and Helen Morrison1*

Open Access

Abstract

Mutagenic loss of the NF2 tumor suppressor gene encoded protein merlin is known to provoke the hereditary
neoplasia syndrome, Neurofibromatosis type 2 (NF2). In addition to glial cell-derived tumors in the PNS and CNS,
disease-related lesions also affect the skin and the eyes. Furthermore, 60% of NF2 patients suffer from peripheral
nerve damage, clinically referred to as peripheral neuropathy. Strikingly, NF2-associated neuropathy often occurs in
the absence of nerve damaging tumors, suggesting tumor-independent events. Recent findings indicate an important
role of merlin in neuronal cell types concerning neuromorphogenesis, axon structure maintenance and communication
between axons and Schwann cells. In this review, we compile clinical and experimental evidences for the
underestimated role of the tumor suppressor merlin in the neuronal compartment.
Keywords: Neurofibromatosis type 2, Merlin isoforms, Peripheral neuropathy, Axon-Schwann cell interaction,
Tumor development, Intelligence

The hereditary disease Neurofibromatosis type 2
Mutations in the NF2 gene are causative for the autosomal-
dominant disease Neurofibromatosis Type 2 (NF2). This
rare multiple neoplasia syndrome affects about 1 in 25,000
live births [1]. However, recent population studies suggest
that up to 1 in 300 people will develop a tumor with an
underlying sporadic NF2 mutation during their lifetime [2].
The heritable NF2 disease is mainly characterized by the
development of benign Schwann cell-derived tumors, called
schwannomas, due to the mutagenic loss of the tumor
suppressor merlin. The hallmark feature of NF2 is the bi-
lateral occurrence of schwannomas at the eighth cranial
nerve (vestibular schwannoma). These tumors regularly
develop in close vicinity to the â€˜Obersteiner-Redlich zoneâ€™
[3] â€“ the boundary between CNS and PNS â€“ where the
transition between Schwann cell and oligodendrocyte mye-
lination takes place. Compressive effects of the schwannoma
onto the vestibulo-cochlear nerve may subsequently result
in loss of hearing and balance. In addition to vestibular
schwannomas and schwannomas occurring within the
spinal cord and along peripheral nerves, mutations in the
NF2 gene are responsible for virtually all non-hereditary,

* Correspondence: helen@fli-leibniz.de
1Leibniz Institute for Age Research, Fritz Lipmann Institute, Beutenbergstrasse
11, D-07745 Jena, Germany
Full list of author information is available at the end of the article

sporadically occurring schwannomas and 50% of sporadic
meningioma cases [4].

However, NF2 is a clinical syndrome that presents with
a variety of other clinical manifestations. In addition to tu-
mors of various entities, NF2 patients suffer from disease-
related lesions affecting the skin and the eyes (for detailed
review see [5]). Most affected individuals will develop
damage to peripheral nerves (peripheral neuropathy) in
their lifetime, another common clinical feature in NF2. To
date, the pathogenesis of NF2-related neuropathy is not
completely understood. Taken together, due to a variety of
organ systems being affected by NF2 disease, affected indi-
viduals may suffer from severe morbidity in addition to
their tumor burden.

Mutations affecting the NF2 gene may become apparent
through at least three kinds of different genetic alterations.
Firstly, inherited mutations due to germline mutations re-
sult in the loss of one allele; these are accompanied by
somatic alterations in the other allele, which cause the
hereditary Neurofibromatosis Type 2. Secondly, sporadic
schwannomas depend on the acquired somatic mutations
in both alleles of the NF2 gene. Thirdly, as we will discuss
later, NF2-related neuropathy may result from the loss of
just one allele as a consequence of cell type-specific hap-
loinsufficiency in neuronal cell types.

Â© 2014 Schulz et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.

Schulz et al. Acta Neuropathologica Communications 2014, 2:82
http://www.actaneurocomms.org/content/2/1/82

Page 2 of 10

Open questions
The tumor suppressor protein merlin, responsible for
NF2, is ubiquitously expressed in all tissues during all
periods of development [6]. Homozygous deletion of
merlin in mice leads to embryonic failure, even before
gastrulation [7]. Moreover, conditional ablation of merlin
during embryogenesis results in a global tissue fusion
defect [8], indicating the importance of merlin from the
earliest stage of development. While the role of merlin
in glial cell types has been extensively characterized dur-
ing both development and adulthood, the expression
and function in non-tumor related tissues has only occa-
sionally been subjected to mainstream NF2 research.

Microenvironment considerations have become a large
field of interest in life science; no given cell type can be
comprehensively considered without the context of its en-
vironment. Cells in direct or close vicinity influence their
neighboring cells - effecting tissue homeostasis. Schwann
cells, the origin for NF2-related tumors, are in tight and
direct contact with axons-resulting in extensive inter-
cellular crosstalk and provoking the hypothesis that axons
and/or axon-derived signals, respectively, contribute to
tumorigenic activity of Schwann cells. We propose that an
exclusive focus on Schwann cell biology in NF2 research
risks neglecting not only other high-prevalence symptoms,
which occur in NF2 disease, but also potential microenvi-
ronmental issues that could contribute to NF2 tumorigen-
esis. For instance, peripheral neuropathy has been found
to appear in individuals who bear mutations in just one
merlin allele and lack a significant load of potentially com-
pressive Schwann cell tumors [9]. This led us to the idea
that merlin expressed in neurons might have functions
unrelated to its tumor suppressor role in glial cells [10].

The tumor suppressor protein merlin
The human NF2 gene on Chromosome 22q12.2 comprises
17 exons that encode for the 595 amino acid protein mer-
lin; also known as schwannomin [11,12]. This actin-binding
protein belongs to the ezrinâ€“radixinâ€“moesin (ERM) family
of proteins that organizes and links membrane proteins to
the cortical cytoskeleton [13]. Merlin mediates contact in-
hibition of proliferation in multiple cell types, including
Schwann cells [14] and is reported to target many signal-
ing components to restrict proliferation [15]. For an ex-
tensive review of merlin effected pathways please see [16].
Moreover, the tumor suppressor merlin activity is sug-
gested to take place in various cellular compartments, in-
cluding the cell nucleus [17,18], at the plasma membrane
[14,19], in endosomes [20] and even in association with
mitotic spindles during mitosis [21]. Although merlin
interacts with a high number of different molecules (for
detailed review see [22]) in different locations of the cell,
we still conclude that part of merlinâ€™s tumor suppressor
activity is at the plasma membrane - mediating contact

inhibition of proliferation by regulating several small
GTPases like Ras or the Rho GTPase family, as well as
the Hippo pathway [23].

Rho GTPases in neuronal cell types
GTPase proteins are molecular switches that regulate many
important processes in the cell, including the organization
of the actin cytoskeleton [24]. By provoking local actin re-
arrangements, the protein family of Rho GTPases is essen-
tial for the development of highly polarized cells like
neurons [25]. Regulators of these small GTPases are there-
fore of special interest in the broad field of neuromorpho-
genesis. Merlin has often been shown to exert its various
functions through Rho GTPases by determining their acti-
vation state [15,26,27]. While GDP-bound molecules are
considered to be inactive, GTP-bound proteins actively
act on their downstream targets. Considering the signifi-
cant importance of small GTPases in neuromorphogen-
esis, merlin, as well as other regulators of small GTPase
activity, are plausible candidates for involvement in the
vastly complex process of neuronal shape determination.
Significantly, mutations in regulators and effectors of Rho
GTPases have been associated with diseases of the ner-
vous system,
including mental retardation and motor
neuron diseases [28].

The appearance of merlin isoforms
The human gene NF2 and its close homologue the murine
gene Nf2 are subject to alternative splicing [29]. By far the
most abundant isoforms are isoform 1 (595 aa) and isoform
2 (590 aa), which differ in their last 11 and 16 amino acids,
respectively [6]. While merlin isoform 1 contains exon 17
instead of exon 16, merlin isoform 2 contains the stop
codon bearing exon 16, which results in a C-terminal
truncated protein [6].

The altered C-terminus of isoform 2 is hydrophilic and
positively charged, while the isoform 1 C-terminus is much
less hydrophilic and has no net charge. As a consequence
isoform 1 C-terminus binds strongly to the N-terminal
FERM domain, while the isoform 2 C-terminus shows only
weak binding [30]. Apparently, both C-termini can interact
with each other, proposing the formation of
isoform
hetero-dimers [31]. Due to the structural and charge differ-
ences in their very C-terminus, the two main merlin iso-
forms are likely to have different binding partners in cases
where the C-terminus is necessary for protein-protein in-
teractions. So far, only syntenin, an adaptor protein in-
volved in the subcellular trafficking of receptors, has been
shown to specifically interact with the C-terminus of iso-
form 1 [32]. Although merlin has been implicated in recep-
tor trafficking [33], the functional consequence of a specific
merlin isoform 1 interaction has not been described.

To date, it remains controversial as to whether both
major merlin isoforms exert a tumor suppressive function.

Schulz et al. Acta Neuropathologica Communications 2014, 2:82
http://www.actaneurocomms.org/content/2/1/82

Page 3 of 10

No pathogenic mutation that specifically hits one isoform
of NF2 has been described; tumorigenic mutations always
inactivate both isoforms [34,35]. The only data on func-
tional differences of the two merlin isoforms comes from
in vitro studies: Of the two major merlin isoforms, only
isoform 1 was originally thought to have proliferation sup-
pressive potential [36,37]. However, more recent studies
suggest that both isoforms have equal proliferation inhi-
biting functions and so far act similarly in most ana-
lyzed assays [38-40]. Despite structural differences in
the C-terminus, it is reasonable to assume that both iso-
forms have partially overlapping functions whenever the
homologous N-terminus is involved in the regulation of
downstream pathways. Furthermore, in an intact cellular
system, differences between the two major merlin iso-
forms may be due to their potential sites of activity -
which could be determined by specific isoform binding
partners targeting them to distinct cellular and subcellular
localizations [41]. Clearly, greater focus and effort is re-
quired to identify and catalogue merlin isoforms and their
functions. Early studies investigating the spatiotemporal
expression pattern of NF2/Nf2 isoforms suggest that mer-
lin plays a pivotal role in neuronal tissue, especially during
development. High NF2 expression was found in brains of
humans [42,43] as well as rodents [6,44]. Interestingly,
Gutmann et al. reported an increase in isoform 2 expres-
sion during neuronal maturation in the cerebral cortex
and cerebellum. Additionally, compared to embryonic tis-
sue, neuronal tissue was one of the few organs to retain
high expression levels of Nf2 in adult rats [6]. However, a
relevant function of merlin isoform 2, in neurons or other
cell types, remained elusive. Only recently have we been
able to decipher a unique function for merlin isoform 2;
wherein this specific isoform is located and operates in
the axonal compartment of neurons [45].

Expression pattern of merlin in neuronal cells
Although merlin has been studied primarily in glial cells,
due to loss of merlin primarily attracting attention by
causing benign tumors, several
lines of evidence now
support additional and functional roles of merlin in neu-
rons. To date, several studies have reported protein ex-
pression of merlin in different types of neuronal cells of
both the PNS and CNS.

Through different imaging techniques such as immu-
nohistochemistry and in-situ-hybridization, merlin has
been detected in sciatic nerve axons [45],
in neurons
that belong to autonomic ganglia in the intestinal tract
[46] and in dorsal root ganglion cells of the PNS [45].

In the CNS, merlin appears in motor neurons of the
spinal cord [47], cortical neurons [26,44,47], hippocam-
pal neurons [26,48], neurons of cranial nerve ganglia
[47] and in cerebellar Purkinje cells [26,46,47,49]. Par-
ticularly in Purkinje cells of the cerebellum, merlin could

be functionally associated with neuromorphogenesis and
dendritic arborization through the regulation of the small
GTPase Rac1 [26]. Furthermore, embryonic expression of
merlin in neural stem cells could be demonstrated in
neuroepithelial cells of the neural tube, as well as in the
ventricular and subventricular zone of the developing brain
[8,50]. The analysis of brain tissue and neuronal progenitor
cell (NPC) cultures showed consistently that merlin is pre-
dominantly present in neurons [51].

On the subcellular level, neuronal merlin was found to
be expressed in dendrites [26], in axons [45,52], in the
cytoplasm [47,53] and in neuronal synaptic junctions [51].
Conclusively, there is now consistent and broad evidence
for a neuronal expression of the tumor suppressor merlin
in both rodent and human tissue. However, little is known
yet to explain merlinâ€™s function in each cell type. This dis-
crepancy clearly needs to be addressed in the future.

Polyneuropathy in NF2 patients
Besides the development of multiple gliogenic tumors af-
fecting both the PNS and CNS, many NF2 patients will de-
velop peripheral neuropathy during their lifetime. Affected
individuals can suffer from stocking-like hypoalgesia (re-
duced sensitivity to pain) and hypesthesia (decreased tactile
sensibility) as well as loss of vibration sense (pallhypesthe-
sia). Patients may also present with a distal reflex loss that
can be followed by a slow but progressive distal muscle
atrophy and paresis in later stages of the disease [54]. Usu-
ally, peripheral neuropathy can occur as a rather local
phenomenon (mononeuropathy simplex or multiplex) or
a more generalized event (polyneuropathy).

Indeed, the exact proportion of NF2 sufferers who de-
velop peripheral nerve damage remains obscure, as
prevalence numbers vary largely. In a huge clinical study,
peripheral nerve lesions unrelated to tumor masses were
observed in 6% of patients suffering from NF2 [55]. An-
other investigation, with primary focus on NF2-related
neuropathy, found that clinical signs manifesting as periph-
eral neuropathy occurred in 47% of investigated patients
[56]. Further electrophysiological examination even re-
vealed evidence of neuropathy in 67% of those individuals.
The general observation that many NF2 patients present
with areflexia, which cannot be completely explained
by the actual tumor load, suggests that subclinical or
masked neuropathy is potentially underdiagnosed in NF2
disease [57].

Electrophysiological methods as a diagnostic tool for
neuromuscular diseases
Electrophysiological measurements are an indispensable
tool for investigating the functional integrity of peripheral
nerves in both the clinical and laboratory environment [58].
In humans, a large number of neuromuscular disorders
and neuropathies diagnostically rely on electrophysiological

Schulz et al. Acta Neuropathologica Communications 2014, 2:82
http://www.actaneurocomms.org/content/2/1/82

Page 4 of 10

measurements. By measuring nerve properties as conduc-
tion velocity or potential amplitudes of the signal, it is
possible to characterize the origin of peripheral nerve
diseases. The nerve conduction velocity is highly dependent
on rapid signal propagation enabled by myelination.
Therefore, demyelinating processes generally show de-
creased conduction velocities. When significantly reduced,
the compound motor action potential (CMAP) â€“ correlat-
ing with the number of functional axons â€“ is an indicator
for axonal damage. Hence, by means of electrophysio-
logical methods, the etiology of peripheral nerve damage
can be discriminated; such as for hereditary neuropathies,
diabetic neuropathy, chronic inflammatory demyelinating
polyneuropathies (CIDP) or metabolic neuropathies.

Exploring the pathogenesis of NF2-related neuropathy
Originally, schwannomas were held to primarily account
for observable neuropathic symptoms developing in the
course of NF2 [59]. Schwannomas can occur within the
spinal cord, on spinal nerve roots, along peripheral nerves
and around cranial nerves â€“ with the vestibular nerve being
the most frequently involved cranial nerve. The localization
of a given tumor naturally determines the presenting fea-
tures and symptoms of an individual, e.g. affections of a
spinal nerve root by a tumor may cause motoric and sen-
sory problems that are clearly related to its innervation
area. However, for the most part, clinical signs of neur-
opathy appear independently from the site of peripheral
nerve schwannomas. In single NF2 patients, polyneurop-
athy even developed years before other NF2-related symp-
toms, like tumors, became evident [56].

Although benign in nature, schwannomas are thought
to produce pain and other symptoms by compressive ef-
fects, thereby impairing axonal integrity in a given nerve.
However, the clinical appearance of neuropathy can hardly
be explained by the tumor burden alone. Concretely, in
some NF2 patients suffering from polyneuropathy, muscle
weakness occurs without significant spinal or peripheral
nerve tumor burden, suggesting that factors other than
gross tumor growth might be responsible for this disorder
[60]. Besides, surgical resection of gross tumor load along
peripheral nerves often lacks a beneficial outcome for af-
fected individuals in terms of neuropathic symptoms [61].
Furthermore, NF2-associated polyneuropathy typically in-
volves more than two peripheral nerves and predomin-
antly affects extremities in a distal and symmetric fashion
[56,62,63], suggesting a systemic rather than local issue.
Thus, tumorlets - hyperproliferative Schwann cells â€“ are
also unlikely to explain the complete etiology of per-
ipheral neuropathy in these patients [9]. However, a high-
resolution MRI study â€“ aiming to link tumor load with
severity of polyneuropathy in NF2 patients â€“ indicated that
non-compressive fascicular microlesions along peripheral
nerves, correlated with severity of clinical symptoms of

NF2-related neuropathy. Apart from that, compressive
tumor macrolesions were absent in most neuropathy-
affected extremities [61].

Both neuropathological and electrophysiological

in-
vestigations initially suggested that NF2-related poly-
neuropathy might develop independently of large solitary
schwannomas [64]. Hagel et al. provided evidence for an
axon-intrinsic pathogenesis of neuropathy in sural nerve
biopsies indicated by pathological reduction of nerve fiber
densities, accompanied by diffuse proliferation of Schwann
cells. Onion bulbs, pathological indicators of repetitive de-/
remyelination, were just seen in a subset of investigated pa-
tients [60]. Furthermore, by determining nerve conduction
properties, two studies were able to show that NF2-related
peripheral neuropathy is commonly of axonal origin
[56,61]. In the majority of cases, the nerve conduction
velocity appeared normal (above the reference levels of
the tested nerves), while CMAP values were markedly
decreased â€“ a diagnostic combination suggestive of axonal
neuropathy.

It was previously hypothesized that NF2 and axonal
neuropathies would exist as independent diseases [65,66].
Our group recently deciphered a promising pathomechan-
ism indicating how the loss of merlin could contribute to
the development of NF2-related neuropathy in an axon-
intrinsic manner [45]. Specifically, via the GTPase Rho/
RhoKinase signaling network, merlinâ€™s splice variant iso-
form 2 promotes phosphorylation of neurofilaments that
are neuron-specific intermediate filaments essential for
axon structure and caliber [67]. Using a mouse model
bearing loss of merlin isoform 2, as well as sural nerve bi-
opsies of NF2 patients, we could show that proper merlin
signaling in axons (see Figure 1) is essential for axon
structure maintenance [45]. Strikingly, heterozygous dele-
tion of Nf2 isoform 2 caused haploinsufficiency in vivo.
This is consistent with clinical findings that NF2 germline
mutations are sufficient to cause polyneuropathy; the loss
of the second allele is not required in humans [9].

Merlin in axon-Schwann cell interactions
The implication of merlin in prevention of Schwann cell
tumorigenesis has been extensively studied [10,69]. NF2-
related schwannomas are encapsulated tumors composed
almost entirely of Schwann cells perched on, but not
commingled with, normal nerve bundles [70]. However,
the benign dignity of NF2-associated Schwann cell-derived
tumors is accompanied by sparse response to classical
chemotherapy [71].

Importantly, the role of merlin in Schwann cells is not
just restricted to its tumor suppressive function. It has
been reported to play a critical role in the control of
Schwann cell numbers and is necessary for the correct
organization and regulation of axo-glial heterotypic con-
tacts [72]. Consistently, merlin in Schwann cells has been

Schulz et al. Acta Neuropathologica Communications 2014, 2:82
http://www.actaneurocomms.org/content/2/1/82

Page 5 of 10

Schwann cells

merlin
iso2

Rho
GAP

Rho
GDI

microtubules

Rho GDP

P 

P 

P 

P 

P 

P 

P 

P 

P 

Rho

GTP

ROCK

axon

neurofilaments 

Figure 1 Potential role for merlin isoform 2 in NF2-related neuropathy. Merlin isoform 2 in axons assembles a multi-protein complex with
RhoGDI [68] and RhoGAP that leads to the local activation of the small GTPase RhoA by GTP loading [45]. This results in subsequent neurofilament
phosphorylation through Rho-associated kinase (ROCK). The specific loss of merlin isoform 2 can therefore provoke irregular neurofilament
phosphorylation and impaired axon structure maintenance.

reported to promote their alignment along axons and ul-
timately influences myelin segment length [73].

Generally, the behavior of Schwann cells is strictly
under the control of axonal signals, both during devel-
opment and in adulthood [74]. As such, Schwann cell
actions should not be assessed solely by endogenous
Schwann cell signaling pathways, but rather with respect
to the influence of axons and vice versa. Signals from
axons regulate the intimate communication of Schwann
cells with axons of the PNS, provide proliferative and sur-
vival signals, and determine the polarization and differen-
tiation programs to either non-myelinating or myelinating
phenotypes [75,76]. Moreover, axonal damage triggers
rapid Schwann cell de-differentiation and this is ac-
companied by myelin breakdown, Schwann cell detachment
from axons and subsequent proliferation [77]. Typically,
patients with NF2 present with different types of benign
Schwann cell tumors, in which most Schwann cells lose
contact with axons [70,78]. Focusing on the pathogenesis
of polyneuropathy affecting NF2 patients, Sperfeld and
colleagues [56] also suggested that the nerve damaging
disease could possibly occur because Schwann cells can
no longer adhere properly to the axons. This underlines
the importance of the microenvironment of peripheral
nerves, where damage to one cell type invariably leads to
pathophysiological changes in the other [79].

The literature contains several reported observations
suggesting that neuronally expressed merlin could also

be involved in the tightly regulated crosstalk between axonal
processes and Schwann cells. For instance, N-terminal
merlin can be associated with Caspr/paranodin, an axonal
transmembrane glycoprotein enriched at paranodal junc-
tions and important for the reciprocal axo-glial signaling
[80]. Merlin also interacts with Î²II-spectrin - another mol-
ecule supporting the axonal cytoskeleton at paranodes
(see Table 1) - essential
for myelinated axon domain
organization [30,49,81]. Paranodal junctions, in general,
are specialized molecular domains of myelinated axons
that are thought to promote adhesion between Schwann
cells and axons (for detailed review see [82]). This data
implies that neuronally expressed merlin could be directly
involved in the mechanism determining proper axon-
Schwann cell contact formation.

Cell type; species
DRG, sciatic nerve lysates (mouse)

Table 1 Binding or interaction partners of neuronal merlin
Reference
Protein
Neurofilaments
[45]
RiÎ² (PKA subunit)
Î²II-spectrin
Caspr/paranodin

brain extracts (rat)

brain lysates (rat)

Purkinje cells

[83]

[30,49]

[80]

Paxillin

RhoGDI

neuroblastoma cells (mouse)

Cell lysate from primary
neurons (mouse)

[84]

[45,68]

p190RhoGap

Sciatic nerve lysates (mouse)

[45]

Schulz et al. Acta Neuropathologica Communications 2014, 2:82
http://www.actaneurocomms.org/content/2/1/82

Page 6 of 10

Recently, we analyzed the impact of neuronally expressed
merlin on the best-characterized signaling cascade between
axon and Schwann cells, namely the Neuregulin1 - ErbB2/
3 pathway [85]. We were intrigued to find that the Neure-
gulin splice variant Nrg1 type III, expressed on axonal
membranes as a juxtacrine growth factor molecule for
Schwann cells, shows reduced expression following loss of
merlin in vitro and in vivo (see Figure 2). In contrast to
merlin isoform 2, which is specifically implicated in axon
structure maintenance, both major merlin isoforms appear
to have equal potency in affecting Nrg1 type III.

In accordance, human sural nerve biopsies taken from
NF2 patients suffering from polyneuropathy display a
strong and consistent reduction of Nrg1 type III. This is
accompanied by a compensatory up-regulation of ErbB2
expression on Schwann cells; as analyzed in mice bear-
ing neuron-specific merlin knockout as well as NF2 pa-
tient samples. Notably, the expression abnormalities of
both Nrg1 type III and ErbB2 receptor appear to be very
specific to NF2 disease and much more pronounced
than in other axonal types of neuropathies [85].

ErbB2/ErbB3 heterodimers are neuregulin receptors
which are required for SC development [86]. In mature
peripheral nerves, Nrg1 participates in the regeneration
and re-myelination of injured myelinated fibers, pro-
cesses that involve SC de-differentiation, proliferation
and re-differentiation to a myelinating phenotype [87].

Interestingly, ErbB2/3 receptor overexpression has
been linked to the pathogenesis of one type of de-
myelinating neuropathy occurring in the course of
Charcot-Marie-Tooth disease type 1 [88], which raises
the possibility of Schwann cell-autonomous effects on
the development of neuropathies.

Remarkably, the loss of merlin in primary Schwann cells
is associated with elevated levels of ErbB receptors [33].
Furthermore, merlin in Schwann cells interacts with CD44
[14], a membrane glycoprotein that enhances neuregulin-
induced ErbB2 phosphorylation [89]. Concerning the
regulation of ErbB2/3 receptor expression, merlin obvi-
ously has synergistic functions in neurons and Schwann
cells, arguing for a holistic function of merlin in both cel-
lular compartments of peripheral nerves. Consequently,
ErbB2/3 receptor overexpression has been identified as a
potential target for NF2 therapy [90], using the monoclo-
nal antibody Trastuzumab [91] or the tyrosine kinase in-
hibitor Lapatinib [92].

Axons are thought to maintain Schwann cells in a differ-
entiated state during adulthood, to ensure the correct
functioning of the nerve [75,76]. It is therefore reasonable
to assume that misregulation of axon surface proteinsâ€“
essential
for Schwann cell alignment and differenti-
ation â€“ could contribute to the initial events in tumor
development. Notably, a comparable pathogenesis is likely
to occur in the related tumor syndrome Neurofibromatosis

Internode

Paranode

Ranvier Node

Paranode

Schwann cell

merlin

ErbB2/3

CD44

Nrg1 type III

Caspr/paranodin

II-spectrin

merlin

neurofilaments

Axon

Figure 2 Interaction of neuronally expressed merlin with axonal proteins essential for axon-Schwann cell signaling. Merlin in neurons
has been shown to interact with two axonal proteins in the paranode region of myelinated axons: Caspr/paranodin [80] and Î²II-spectrin [30].
Furthermore, merlin regulates the expression of Nrg1 type III [85], an axon surface molecule with growth factor-like impact on Schwann cell
behavior. Interestingly, the receptor of Nrg1 type III on Schwann cells, ErBB2/3 [33] as well as its co-receptor CD44 [14], is regulated by merlin
expressed in Schwann cells.

Schulz et al. Acta Neuropathologica Communications 2014, 2:82
http://www.actaneurocomms.org/content/2/1/82

Page 7 of 10

Type 1 (NF1); possibly the most common inherited dis-
order caused by a single gene, which is characterized by
the development of multiple neurofibromas. Since hetero-
typic cellâ€“cell contacts control cell proliferation and sup-
press tumorigenesis [93], the loss of Schwann cell contact
to axons is a frequent and important early event in tumor
development for these highly heterotypic benign tumors of
the peripheral nerve sheath. Joseph et al. [94] could add-
itionally show that NF1-related tumors arise from differen-
tiated glial cells instead of undifferentiated neural crest
cells. These results further support the hypothesis that
Schwann cell detachment from axons is an important early
event in tumor development â€“ a mechanism neuronally
expressed merlin could be also involved in concerning
NF2 disease. Taken together, new findings on merlin in the
neuronal compartment suggest pathogenesis of NF2 dis-
ease, wherein the NF2 gene encoded protein has cell type-
dependent functions in order to prevent tumor formation.

Concluding remarks
In a recent study [45] the impressive number of proteins
merlin can interact with was further expanded (for de-
tailed review see [22]). More precisely, merlin has now
been reported to associate with all three classes of cyto-
skeletal elements; namely actin filaments [95], microtubules
[21,96] and intermediate filaments [45]. This connection
underlines merlinâ€™s fascinating role as a versatile cytoskel-
eton associated molecule involved in a vast variety of sig-
naling events. This makes merlin a highly enigmatic and
extraordinary tumor suppressor. However, the contribu-
tion of merlin splice variants may play an additional role
for the interaction with multiple proteins in a large variety
of different cell types.

According to Knudsonâ€™s two-hit-hypothesis, merlin acts
as a classical tumor suppressor. Interestingly, inactivating
mutations of merlin seem to have tissue-dependent di-
verse effects. Loss of heterozygosity, the functional
loss
of one gene allele in which the other allele was already
inactivated, is known to be crucial for merlin owed tumor
formation in Schwann cells [97,98]. However, deficient
effects due to loss of merlin can already be detected in
neurons where only one mutation is verifiable [9]; thus
explaining why polyneuropathy in NF2 patients is fre-
quently found in the absence of compressive tumors and
may even appear chronologically earlier. In line with this
notion, axons of mice heterozygous for merlin isoform 2
mutations show functional and morphological abnormal-
ities [45]. However, despite the clear relevance of merlin
in neuronal cells of the PNS, a functional role for merlin
in CNS neurons remains elusive.

GrÃ¶nholm et al. [83] provided a first functional hint for
neuronally expressed merlin in the CNS. It was shown to
be the first known binding partner of RiÎ², a regulatory
subunit of protein kinase A (PKA), which is evidently

implicated in learning-related functions [99]. Consistently,
Wassink and colleagues [100] reported that merlin is a
candidate gene for the development of autism spectrum
disorder (ASD), which has been shown to be associated
with dendritic spine abnormalities [101]. Because den-
dritic spine morphology is in turn highly susceptible to
the activation state of small GTPases [102], an impact of
merlin on spine morphology and/or plasticity is very likely
but, as yet, defies characterization. In line with this hy-
pothesis, the loss of merlin in neural progenitor cells re-
sults in severe reduction in hippocampus size [50]; the
implications of which in learning and memory acquisition
are indisputable. However, despite merlinâ€™s theoretical im-
plication in learning and memory acquisition, no study
has ever suggested changes in NF2 patientsâ€™ intelligence
or cognitive performance. If such potential effects on
learning and memory were to exist, these could be rather
subtle and/or hidden by the vast environmental noise that
envelops human intelligence.

Outstanding questions
 How can future disease models and considerations
regarding NF2 pathogenesis better emphasize the
importance of the nerve microenvironment?
 Does the loss of neuronal merlin and its influence
on Schwann cell behavior impair peripheral nerve
regeneration following injury?
 Does merlin deficiency in neurons contribute to
 Is the downstream signaling of axonal merlin

NF2-related schwannoma formation?

isoform 2 â€“ involving RhoA and ROCK â€“ relevant
for other hereditary neuropathies whose
mechanisms have yet to be deciphered?

 Are Schwann cell-autonomous effects of merlin due

to loss-of-heterozygosity sufficient to promote
NF2-related neuropathy without any disturbances in
the axonal compartment?

 Are there alterations in cognitive performances in
merlin-deficient animals and patients suffering from
the NF2 disease?

 What are the specific functions of the two major

merlin isoforms? Is there a cell type-specific
expression? With regard to the variety of different
merlin functions, which merlin isoforms can
compensate for each other?

Competing interests
The authors declare no competing financial interests.

Acknowledgements
The authors would like thank to Prof. Stephan Baader for critical reading of
the manuscript and valuable suggestions. This work was supported by SFB
604, DFG MO 1421/2-1 and Krebshilfe 107089. A.S. is a recipient of a Young
Investigator Award from the Childrenâ€™s Tumor Foundation.

Schulz et al. Acta Neuropathologica Communications 2014, 2:82
http://www.actaneurocomms.org/content/2/1/82

Page 8 of 10

Author details
1Leibniz Institute for Age Research, Fritz Lipmann Institute, Beutenbergstrasse
11, D-07745 Jena, Germany. 2Hans Berger Department of Neurology, Jena
University Hospital, Friedrich Schiller University Jena, 07747 Jena, Germany.

Received: 27 May 2014 Accepted: 30 June 2014
Published: 12 July 2014

References
1.

2.

3.

4.

5.

6.

Baser ME, R Evans DG, Gutmann DH (2003) Neurofibromatosis 2. Curr Opin
Neurol 16:27â€“33, doi:10.1097/01.wco.0000053583.70044.ab
Evans DG, Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-
Vuskanovic D, Belzberg A, Bollag G, Chen R, DiTomaso E, Golfinos J, Harris G,
Jacob A, Kalpana G, Karajannis M, Korf B, Kurzrock R, Law M, McClatchey A,
Packer R, Roehm P, Rubenstein A, Slattery W 3rd, Tonsgard JH, Welling DB,
Widemann B, Yohay K, Giovannini M (2009) Consensus recommendations to
accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res
15:5032â€“5039, doi:10.1158/1078-0432.CCR-08-3011
Roosli C, Linthicum FH Jr, Cureoglu S, Merchant SN (2012) What is the site
of origin of cochleovestibular schwannomas? Audiol Neurootol 17:121â€“125,
doi:10.1159/000331394
Lee JH, Sundaram V, Stein DJ, Kinney SE, Stacey DW, Golubic M (1997)
Reduced expression of schwannomin/merlin in human sporadic
meningiomas. Neurosurgery 40:578â€“587
Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR
(2009) Neurofibromatosis type 2. Lancet 373:1974â€“1986, doi:10.1016/S0140-
6736(09)60259-2
Gutmann DH, Wright DE, Geist RT, Snider WD (1995) Expression of the
neurofibromatosis 2 (NF2) gene isoforms during rat embryonic
development. Hum Mol Genet 4:471â€“478

7. McClatchey AI, Saotome I, Ramesh V, Gusella JF, Jacks T (1997) The Nf2

tumor suppressor gene product is essential for extraembryonic
development immediately prior to gastrulation. Genes Dev 11:1253â€“1265
8. McLaughlin ME, Kruger GM, Slocum KL, Crowley D, Michaud NA, Huang J,
Magendantz M, Jacks T (2007) The Nf2 tumor suppressor regulates cell-cell
adhesion during tissue fusion. Proc Natl Acad Sci U S A 104:3261â€“3266,
doi:10.1073/pnas.0700044104
Hanemann CO, Diebold R, Kaufmann D (2007) Role of NF2 haploinsufficiency
in NF2-associated polyneuropathy. Brain Pathol 17:371â€“376, doi:10.1111/j.1750-
3639.2007.00086.x

9.

10. Ramesh V (2004) Merlin and the ERM proteins in Schwann cells, neurons

and growth cones. Nat Rev Neurosci 5:462â€“470, doi:10.1038/nrn1407
11. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C,

12.

Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, Pulst SM, Lenoir G,
Bijlsma E, Fashold R, Dumanski J, de Jong P, Parry D, Eldrige R, Aurias A,
Delattre O, Thomas G (1993) Alteration in a new gene encoding a putative
membrane-organizing protein causes neuro-fibromatosis type 2. Nature
363:515â€“521, doi:10.1038/363515a0
Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM,
Eldridge R, Kley N, Menon AG, Pulaski K, Haase VH, Ambrose CM, Munroe D,
Bove C, Haines JL, Martuza RL, MacDonald ME, Seizinger BR, Short MP,
Buckler AJ, James F, Gusella JF (1993) A novel moesin-, ezrin-, radixin-like
gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell
72:791â€“800

13. McClatchey AI, Fehon RG (2009) Merlin and the ERM proteinsâ€“regulators of

receptor distribution and signaling at the cell cortex. Trends Cell Biol
19:198â€“206, doi:10.1016/j.tcb.2009.02.006

14. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, Gutmann
DH, Ponta H, Herrlich P (2001) The NF2 tumor suppressor gene product,
merlin, mediates contact inhibition of growth through interactions with
CD44. Genes Dev 15:968â€“980, doi:10.1101/gad.189601

15. Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P (2007)

Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the
activation of Ras and Rac. Cancer Res 67:520â€“527, doi:10.1158/0008-5472.
CAN-06-1608
Li W, Cooper J, Karajannis MA, Giancotti FG (2012) Merlin: a tumour
suppressor with functions at the cell cortex and in the nucleus. EMBO Rep
13:204â€“215, doi:10.1038/embor.2012.11

16.

17. Muranen T, Gronholm M, Renkema GH, Carpen O (2005) Cell cycle-dependent

nucleocytoplasmic shuttling of the neurofibromatosis 2 tumour suppressor
merlin. Oncogene 24:1150â€“1158, doi:10.1038/sj.onc.1208283

18.

Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini
M, Hanemann CO, Long SB, Erdjument-Bromage H, Zhou P, Tempst P,
Giancotti FG (2010) Merlin/NF2 suppresses tumorigenesis by inhibiting the
E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 140:477â€“490,
doi:10.1016/j.cell.2010.01.029

19. Mani T, Hennigan RF, Foster LA, Conrady DG, Herr AB, Ip W (2011) FERM

20.

domain phosphoinositide binding targets merlin to the membrane and is
essential for its growth-suppressive function. Mol Cell Biol 31:1983â€“1996,
doi:10.1128/MCB.00609-10
Scoles DR, Huynh DP, Chen MS, Burke SP, Gutmann DH, Pulst SM (2000)
The neurofibromatosis 2 tumor suppressor protein interacts with
hepatocyte growth factor-regulated tyrosine kinase substrate. Hum Mol
Genet 9:1567â€“1574

21. Muranen T, Gronholm M, Lampin A, Lallemand D, Zhao F, Giovannini M,

Carpen O (2007) The tumor suppressor merlin interacts with microtubules
and modulates Schwann cell microtubule cytoskeleton. Hum Mol Genet
16:1742â€“1751, doi:10.1093/hmg/ddm122
Scoles DR (2008) The merlin interacting proteins reveal multiple targets for
NF2 therapy. Biochim Biophys Acta 1785:32â€“54, doi:10.1016/j.
bbcan.2007.10.001

22.

23. Yin F, Yu J, Zheng Y, Chen Q, Zhang N, Pan D (2013) Spatial organization of

Hippo signaling at the plasma membrane mediated by the tumor
suppressor Merlin/NF2. Cell 154:1342â€“1355, doi:10.1016/j.cell.2013.08.025

24. Hall A (1998) G proteins and small GTPases: distant relatives keep in touch.

25.

26.

27.

Science 280:2074â€“2075
Luo L (2000) Rho GTPases in neuronal morphogenesis. Nat Rev Neurosci
1:173â€“180, doi:10.1038/35044547
Schulz A, Geissler KJ, Kumar S, Leichsenring G, Morrison H, Baader SL (2010)
Merlin inhibits neurite outgrowth in the CNS. J Neurosci 30:10177â€“10186,
doi:10.1523/JNEUROSCI.0840-10.2010
Flaiz C, Kaempchen K, Matthies C, Hanemann CO (2007) Actin-rich
protrusions and nonlocalized GTPase activation in Merlin-deficient
schwannomas. J Neuropathol Exp Neurol 66:608â€“616, doi:10.1097/
nen.0b013e318093e555

28. Nadif Kasri N, Van Aelst L (2008) Rho-linked genes and neurological disorders.

Pflugers Arch 455:787â€“797, doi:10.1007/s00424-007-0385-1

29. Golovnina K, Blinov A, Akhmametyeva EM, Omelyanchuk LV, Chang LS

30.

(2005) Evolution and origin of merlin, the product of the Neurofibromatosis
type 2 (NF2) tumor-suppressor gene. BMC Evol Biol 5:69, doi:10.1186/1471-
2148-5-69
Scoles DR, Huynh DP, Morcos PA, Coulsell ER, Robinson NG, Tamanoi F,
Pulst SM (1998) Neurofibromatosis 2 tumour suppressor schwannomin
interacts with betaII-spectrin. Nat Genet 18:354â€“359, doi:10.1038/ng0498-
354

31. Meng JJ, Lowrie DJ, Sun H, Dorsey E, Pelton PD, Bashour AM, Groden J,

Ratner N, Ip W (2000) Interaction between two isoforms of the NF2
tumor suppressor protein, merlin, and between merlin and ezrin,
suggests modulation of ERM proteins by merlin. J Neurosci Res
62:491â€“502
Jannatipour M, Dion P, Khan S, Jindal H, Fan X, Laganiere J, Chishti AH,
Rouleau GA (2001) Schwannomin isoform-1 interacts with syntenin via PDZ
domains. J Biol Chem 276:33093â€“33100, doi:10.1074/jbc.M105792200
Lallemand D, Manent J, Couvelard A, Watilliaux A, Siena M, Chareyre F,
Lampin A, Niwa-Kawakita M, Kalamarides M, Giovannini M (2009) Merlin
regulates transmembrane receptor accumulation and signaling at the
plasma membrane in primary mouse Schwann cells and in human
schwannomas. Oncogene 28:854â€“865, doi:10.1038/onc.2008.427
Jacoby LB, MacCollin M, Barone R, Ramesh V, Gusella JF (1996) Frequency
and distribution of NF2 mutations in schwannomas. Genes Chromosomes
Cancer 17:45â€“55, doi:10.1002/(SICI)1098-2264(199609)17:1<45::AID-GCC7>3.0.
CO;2-2

32.

33.

34.

35. Baser ME, Kuramoto L, Woods R, Joe H, Friedman JM, Wallace AJ, Ramsden
RT, Olschwang S, Bijlsma E, Kalamarides M, Papi L, Kato R, Carroll J, Lazaro C,
Joncourt F, Parry DM, Rouleau GA, Evans DG (2005) The location of
constitutional neurofibromatosis 2 (NF2) splice site mutations is associated
with the severity of NF2. J Med Genet 42:540â€“546, doi:10.1136/
jmg.2004.029504
Sherman L, Xu HM, Geist RT, Saporito-Irwin S, Howells N, Ponta H,
Herrlich P, Gutmann DH (1997) Interdomain binding mediates tumor
growth suppression by the NF2 gene product. Oncogene 15:2505â€“2509,
doi:10.1038/sj.onc.1201418

36.

Schulz et al. Acta Neuropathologica Communications 2014, 2:82
http://www.actaneurocomms.org/content/2/1/82

Page 9 of 10

37. Gutmann DH, Sherman L, Seftor L, Haipek C, Hoang Lu K, Hendrix M (1999)

57. MacCollin M (1999) Clinical aspects. In: Friedman JM, Gutmann DH,

38.

39.

Increased expression of the NF2 tumor suppressor gene product, merlin,
impairs cell motility, adhesionand spreading. Hum Mol Genet 8:267â€“275,
doi:ddc028
James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov
AO, Gusella JF, Ramesh V (2009) NF2/merlin is a novel negative regulator of
mTOR complex 1, and activation of mTORC1 is associated with meningioma and
schwannoma growth. Mol Cell Biol 29:4250â€“4261, doi:10.1128/MCB.01581-08
Laulajainen M, Melikova M, Muranen T, Carpen O, Gronholm M (2012)
Distinct overlapping sequences at the carboxy-terminus of merlin
regulate its tumour suppressor and morphogenic activity. J Cell Mol
Med 16:2161â€“2175, doi:10.1111/j.1582-4934.2012.01525.x

40. Zhan Y, Modi N, Stewart AM, Hieronimus RI, Liu J, Gutmann DH,

Chadee DN (2011) Regulation of mixed lineage kinase 3 is required for
Neurofibromatosis-2-mediated growth suppression in human cancer.
Oncogene 30:781â€“789, doi:10.1038/onc.2010.453

41. Gavilan HS, Kulikauskas RM, Gutmann DH, Fehon RG (2014) In Vivo
Functional Analysis of the Human NF2 Tumor Suppressor Gene in
Drosophila. PLoS One 9:e90853, doi:10.1371/journal.pone.0090853

42. Bianchi AB, Hara T, Ramesh V, Gao J, Klein-Szanto AJ, Morin F, Menon AG,
Trofatter JA, Gusella JF, Seizinger BR, Kley N (1994) Mutations in transcript
isoforms of the neurofibromatosis 2 gene in multiple human tumour types.
Nat Genet 6:185â€“192, doi:10.1038/ng0294-185
Schmucker B, Tang Y, Kressel M (1999) Novel alternatively spliced isoforms
of the neurofibromatosis type 2 tumor suppressor are targeted to the
nucleus and cytoplasmic granules. Hum Mol Genet 8:1561â€“1570
44. Huynh DP, Tran TM, Nechiporuk T, Pulst SM (1996) Expression of

43.

45.

neurofibromatosis 2 transcript and gene product during mouse fetal
development. Cell Growth Differ 7:1551â€“1561
Schulz A, Baader SL, Niwa-Kawakita M, Jung MJ, Bauer R, Garcia C, Zoch A,
Schacke S, Hagel C, Mautner VF, Hanemann CO, Dun XP, Parkinson DB,
Weis J, Schroder JM, Gutmann DH, Giovannini M, Morrison H (2013) Merlin
isoform 2 in neurofibromatosis type 2-associated polyneuropathy. Nat
Neurosci 16:426â€“433, doi:10.1038/nn.3348

46. den Bakker MA, Vissers KJ, Molijn AC, Kros JM, Zwarthoff EC, van der Kwast

TH (1999) Expression of the neurofibromatosis type 2 gene in human
tissues. J Histochem Cytochem 47:1471â€“1480

47. Claudio JO, Lutchman M, Rouleau GA (1995) Widespread but cell type-specific
expression of the mouse neurofibromatosis type 2 gene. Neuroreport
6:1942â€“1946

48. Wang Q, Zhou D, Yan B, Lin X, Zhang SF (2006) [Expression of Merlin in
cortex of temporal lobe and in hippocampal CA1 region of the Kindling
Model of Epilepsy induced by corciaria lactone in rats]. Sichuan Da Xue Xue
Bao Yi Xue Ban 37:115â€“117

49. Chen Y, Yu P, Lu D, Tagle DA, Cai T (2001) A novel isoform of beta-spectrin
II localizes to cerebellar Purkinje-cell bodies and interacts with neurofibromatosis
type 2 gene product schwannomin. J Mol Neurosci 17:59â€“70,
doi:10.1385/JMN:17:1:59
Lavado A, He Y, Pare J, Neale G, Olson EN, Giovannini M, Cao X (2013)
Tumor suppressor Nf2 limits expansion of the neural progenitor pool by
inhibiting Yap/Taz transcriptional coactivators. Development 140:3323â€“3334,
doi:10.1242/dev.096537

50.

51. Gronholm M, Teesalu T, Tyynela J, Piltti K, Bohling T, Wartiovaara K, Vaheri A,

Carpen O (2005) Characterization of the NF2 protein merlin and the ERM
protein ezrin in human, rat, and mouse central nervous system. Mol Cell
Neurosci 28:683â€“693, doi:10.1016/j.mcn.2004.11.014
Seo PS, Quinn BJ, Khan AA, Zeng L, Takoudis CG, Hanada T, Bolis A, Bolino
A, Chishti AH (2009) Identification of erythrocyte p55/MPP1 as a binding
partner of NF2 tumor suppressor protein/Merlin. Exp Biol Med (Maywood)
234:255â€“262, doi:10.3181/0809-RM-275
Stemmer-Rachamimov AO, Gonzalez-Agosti C, Xu L, Burwick JA, Beauchamp
R, Pinney D, Louis DN, Ramesh V (1997) Expression of NF2-encoded merlin
and related ERM family proteins in the human central nervous system. J
Neuropathol Exp Neurol 56:735â€“742
England JD, Asbury AK (2004) Peripheral neuropathy. Lancet 363:2151â€“2161,
doi:10.1016/S0140-6736(04)16508-2
Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R (1992)
A clinical study of type 2 neurofibromatosis. Q J Med 84:603â€“618
Sperfeld AD, Hein C, Schroder JM, Ludolph AC, Hanemann CO (2002)
Occurrence and characterization of peripheral nerve involvement in
neurofibromatosis type 2. Brain 125:996â€“1004

52.

53.

54.

55.

56.

MacCollin M, Riccardi VM (eds) Johns Hopkins University Press,
Baltimore, pp 299â€“326
Kimura J (2001) Electrodiagnosis in Diseases of Nerve and Muscle: Principles
and Practice. Oxford University Press, USA, City

58.

59. Grazzi L, Chiapparini L, Parati EA, Giombini S, D'Amico D, Leone M, Bussone
G (1998) Type II neurofibromatosis presenting as quadriceps atrophy. Ital J
Neurol Sci 19:94â€“96

60. Hagel C, Lindenau M, Lamszus K, Kluwe L, Stavrou D, Mautner VF (2002)

Polyneuropathy in neurofibromatosis 2: clinical findings, molecular genetics
and neuropathological alterations in sural nerve biopsy specimens. Acta
Neuropathol 104:179â€“187, doi:10.1007/s00401-002-0535-7

62.

63.

61. Baumer P, Mautner VF, Baumer T, Schuhmann MU, Tatagiba M, Heiland S,
Kaestel T, Bendszus M, Pham M (2013) Accumulation of non-compressive
fascicular lesions underlies NF2 polyneuropathy. J Neurol 260:38â€“46,
doi:10.1007/s00415-012-6581-8
Iwata A, Kunimoto M, Inoue K (1998) Schwann cell proliferation as the
cause of peripheral neuropathy in neurofibromatosis-2. J Neurol Sci
156:201â€“204
Iseki C, Takahashi Y, Wada M, Kawanami T, Kurita K, Kato T (2009) A case of
neurofibromatosis type 2 (NF2) presenting with late-onset axonal polyneuropathy.
Rinsho Shinkeigaku 49:419â€“423
Kuo HC, Chen SR, Jung SM, Wu Chou YH, Huang CC, Chuang WL, Wei KC,
Ro LS (2010) Neurofibromatosis 2 with peripheral neuropathies:
Electrophysiological, pathological and genetic studies of a Taiwanese family.
Neuropathology doi:10.1111/j.1440-1789.2009.01099.x

64.

65. Bosch EP, Murphy MJ, Cancilla PA (1981) Peripheral neurofibromatosis and

peroneal muscular atrophy. Neurology 31:1408â€“1414

66. Overweg-Plandsoen WC, Brouwer-Mladin R, Merel P, de Vries L, Bijlsma EK

(1996) Neurofibromatosis type 2 in an adolescent boy with polyneuropathy
and a mutation in the NF2 gene. J Neurol 243:724â€“726

67. Perrot R, Berges R, Bocquet A, Eyer J (2008) Review of the multiple aspects

of neurofilament functions, and their possible contribution to
neurodegeneration. Mol Neurobiol 38:27â€“65, doi:10.1007/s12035-008-8033-0
68. Maeda M, Matsui T, Imamura M, Tsukita S (1999) Expression level, subcellular

distribution and rho-GDI binding affinity of merlin in comparison with
Ezrin/Radixin/Moesin proteins. Oncogene 18:4788â€“4797, doi:10.1038/sj.
onc.1202871

69. Bretscher A, Edwards K, Fehon RG (2002) ERM proteins and merlin: integrators

at the cell cortex. Nat Rev Mol Cell Biol 3:586â€“599, doi:10.1038/nrm882

70. Corfas G, Velardez MO, Ko CP, Ratner N, Peles E (2004) Mechanisms and

roles of axon-Schwann cell interactions. J Neurosci 24:9250â€“9260,
doi:10.1523/JNEUROSCI.3649-04.2004

71. Hanemann CO (2008) Magic but treatable? Tumours due to loss of merlin.

Brain 131:606â€“615, doi:10.1093/brain/awm249

72. Denisenko N, Cifuentes-Diaz C, Irinopoulou T, Carnaud M, Benoit E,

Niwa-Kawakita M, Chareyre F, Giovannini M, Girault JA, Goutebroze L
(2008) Tumor suppressor schwannomin/merlin is critical for the
organization of Schwann cell contacts in peripheral nerves. J Neurosci
28:10472â€“10481, doi:10.1523/JNEUROSCI.2537-08.2008
Thaxton C, Bott M, Walker B, Sparrow NA, Lambert S, Fernandez-Valle C
(2011) Schwannomin/merlin promotes Schwann cell elongation and
influences myelin segment length. Mol Cell Neurosci 47:1â€“9, doi:10.1016/j.
mcn.2010.12.006
Jessen KR, Mirsky R (2005) The origin and development of glial cells in
peripheral nerves. Nat Rev Neurosci 6:671â€“682, doi:10.1038/nrn1746

73.

74.

75. Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C,

76.

77.

Role L, Lai C, Schwab MH, Nave KA (2004) Axonal neuregulin-1 regulates
myelin sheath thickness. Science 304:700â€“703, doi:10.1126/science.1095862
Taveggia C, Zanazzi G, Petrylak A, Yano H, Rosenbluth J, Einheber S, Xu X,
Esper RM, Loeb JA, Shrager P, Chao MV, Falls DL, Role L, Salzer JL (2005)
Neuregulin-1 type III determines the ensheathment fate of axons. Neuron
47:681â€“694, doi:10.1016/j.neuron.2005.08.017
Scherer SS, Salzer JL (2001) Axon-Schwann cell interactions during peripheral
nerve degeneration and regeneration. Glial Cell Dev: Basic Princ Clinl Relevance
2:165â€“196

78. Gijtenbeek JM, Gabreels-Festen AA, Lammens M, Zwarts MJ, van Engelen

BG (2001) Mononeuropathy multiplex as the initial manifestation of
neurofibromatosis type 2. Neurology 56:1766â€“1768
Fricker FR, Bennett DL (2011) The role of neuregulin-1 in the response to
nerve injury. Future Neurol 6:809â€“822

79.

Schulz et al. Acta Neuropathologica Communications 2014, 2:82
http://www.actaneurocomms.org/content/2/1/82

Page 10 of 10

PKA on mossy fiber LTP and its relation to spatial and contextual learning.
Cell 83:1211â€“1222

100. Wassink TH, Brzustowicz LM, Bartlett CW, Szatmari P (2004) The search for

autism disease genes. Ment Retard Dev Disabil Res Rev 10:272â€“283,
doi:10.1002/mrdd.20041

101. Penzes P, Cahill ME, Jones KA, VanLeeuwen JE, Woolfrey KM (2011)

Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci
14:285â€“293, doi:10.1038/nn.2741

102. Murakoshi H, Wang H, Yasuda R (2011) Local, persistent activation of Rho
GTPases during plasticity of single dendritic spines. Nature 472:100â€“104,
doi:10.1038/nature09823

doi:10.1186/s40478-014-0082-1
Cite this article as: Schulz et al.: A neuronal function of the tumor
suppressor protein merlin. Acta Neuropathologica Communications
2014 2:82.

80. Denisenko-Nehrbass N, Goutebroze L, Galvez T, Bonnon C, Stankoff B, Ezan P,
Giovannini M, Faivre-Sarrailh C, Girault JA (2003) Association of Caspr/paranodin
with tumour suppressor schwannomin/merlin and beta1 integrin in the central
nervous system. J Neurochem 84:209â€“221

81. Zhang C, Susuki K, Zollinger DR, Dupree JL, Rasband MN (2013) Membrane
domain organization of myelinated axons requires betaII spectrin. J Cell Biol
203:437â€“443, doi:10.1083/jcb.201308116
Salzer JL, Brophy PJ, Peles E (2008) Molecular domains of myelinated
axons in the peripheral nervous system. Glia 56:1532â€“1540, doi:10.1002/
glia.20750

82.

83. Gronholm M, Vossebein L, Carlson CR, Kuja-Panula J, Teesalu T, Alfthan K,

Vaheri A, Rauvala H, Herberg FW, Tasken K, Carpen O (2003) Merlin links to
the cAMP neuronal signaling pathway by anchoring the RIbeta subunit of
protein kinase A. J Biol Chem 278:41167â€“41172, doi:10.1074/jbc.M306149200
84. Yamauchi J, Miyamoto Y, Kusakawa S, Torii T, Mizutani R, Sanbe A, Nakajima

H, Kiyokawa N, Tanoue A (2008) Neurofibromatosis 2 tumor suppressor,
the gene induced by valproic acid, mediates neurite outgrowth through
interaction with paxillin. Exp Cell Res 314:2279â€“2288, doi:10.1016/j.
yexcr.2008.03.019
Schulz A, Kyselyova A, Baader SL, Jung MJ, Zoch A, Mautner VF, Hagel C,
Morrison H (2014) Neuronal merlin influences ERBB2 receptor expression on
Schwann cells through neuregulin 1 type III signalling. Brain doi:10.1093/
brain/awt327

85.

86. Citri A, Skaria KB, Yarden Y (2003) The deaf and the dumb: the biology of

ErbB-2 and ErbB-3. Exp Cell Res 284:54â€“65

87. Zanazzi G, Einheber S, Westreich R, Hannocks MJ, Bedell-Hogan D, Marchionni

MA, Salzer JL (2001) Glial growth factor/neuregulin inhibits Schwann cell
myelination and induces demyelination. J Cell Biol 152:1289â€“1299

89.

88. Massa R, Palumbo C, Cavallaro T, Panico MB, Bei R, Terracciano C, Rizzuto N,
Bernardi G, Modesti A (2006) Overexpression of ErbB2 and ErbB3 receptors
in Schwann cells of patients with Charcot-Marie-tooth disease type 1A.
Muscle Nerve 33:342â€“349, doi:10.1002/mus.20460
Sherman LS, Rizvi TA, Karyala S, Ratner N (2000) CD44 enhances neuregulin
signaling by Schwann cells. J Cell Biol 150:1071â€“1084
Thaxton C, Lopera J, Bott M, Fernandez-Valle C (2008) Neuregulin and
laminin stimulate phosphorylation of the NF2 tumor suppressor in Schwann
cells by distinct protein kinase A and p21-activated kinase-dependent
pathways. Oncogene 27:2705â€“2715, doi:10.1038/sj.onc.1210923

90.

91. Clark JJ, Provenzano M, Diggelmann HR, Xu N, Hansen SS, Hansen MR
(2008) The ErbB inhibitors trastuzumab and erlotinib inhibit growth of
vestibular schwannoma xenografts in nude mice: a preliminary study. Otol
Neurotol 29:846â€“853, Doi 10.1097/MAO.0b013e31817f7398

92. Ammoun S, Cunliffe CH, Allen JC, Chiriboga L, Giancotti FG, Zagzag D,
Hanemann CO, Karajannis MA (2010) ErbB/HER receptor activation and
preclinical efficacy of lapatinib in vestibular schwannoma. Neuro-Oncology
12:834â€“843, doi:10.1093/neuonc/noq012

93. Parrinello S, Noon LA, Harrisingh MC, Wingfield Digby P, Rosenberg LH,

94.

95.

Cremona CA, Echave P, Flanagan AM, Parada LF, Lloyd AC (2008) NF1 loss
disrupts Schwann cell-axonal interactions: a novel role for semaphorin 4 F.
Genes Dev 22:3335â€“3348, doi:10.1101/gad.490608
Joseph NM, Mosher JT, Buchstaller J, Snider P, McKeever PE, Lim M, Conway
SJ, Parada LF, Zhu Y, Morrison SJ (2008) The loss of Nf1 transiently promotes
self-renewal but not tumorigenesis by neural crest stem cells. Cancer Cell
13:129â€“140, doi:10.1016/j.ccr.2008.01.003
James MF, Manchanda N, Gonzalez-Agosti C, Hartwig JH, Ramesh V (2001)
The neurofibromatosis 2 protein product merlin selectively binds F-actin
but not G-actin, and stabilizes the filaments through a lateral association.
Biochem J 356:377â€“386

96. Xu HM, Gutmann DH (1998) Merlin differentially associates with the

microtubule and actin cytoskeleton. J Neurosci Res 51:403â€“415

97. Hadfield KD, Smith MJ, Urquhart JE, Wallace AJ, Bowers NL, King AT,

Rutherford SA, Trump D, Newman WG, Evans DG (2010) Rates of loss of
heterozygosity and mitotic recombination in NF2 schwannomas, sporadic
vestibular schwannomas and schwannomatosis schwannomas. Oncogene
29:6216â€“6221, doi:10.1038/onc.2010.363
Stemmer-Rachamimov AO, Ino Y, Lim ZY, Jacoby LB, MacCollin M, Gusella
JF, Ramesh V, Louis DN (1998) Loss of the NF2 gene and merlin occur by
the tumorlet stage of schwannoma development in neurofibromatosis 2. J
Neuropathol Exp Neurol 57:1164â€“1167

98.

99. Huang YY, Kandel ER, Varshavsky L, Brandon EP, Qi M, Idzerda RL, McKnight

GS, Bourtchouladze R (1995) A genetic test of the effects of mutations in

Submit your next manuscript to BioMed Central
and take full advantage of: 

â€¢ Convenient online submission

â€¢ Thorough peer review

â€¢ No space constraints or color ï¬gure charges

â€¢ Immediate publication on acceptance

â€¢ Inclusion in PubMed, CAS, Scopus and Google Scholar

â€¢ Research which is freely available for redistribution

Submit your manuscript at 
www.biomedcentral.com/submit

